James R Berenson (James Berenson)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 18

Top Venues

British journal of haematology

European journal of haematology

Hematological oncology

Targeted oncology

James R. Berenson, MD, Inc.

This page only lists publications with an associated author ORCID identifier.

Affiliation History

James R. Berenson, MD, Inc. Jun 2o 2003

United States

President :: Hematology/Oncology

Publications

Samuel David Stampfer, Sean Bujarski, Marissa-Skye Goldwater, Scott Jew, Bernard Regidor, Haiming Chen, Ning Xu, Mingjie Li, Eddie Fung, Regina Swift, Bethany Beatty, Shahrooz Eshaghian, James R Berenson
Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma. Cancer reports (Hoboken, N.J.) (2023)
Scott Jew, Sean Bujarski, Bernard Regidor, Marsiye Emamy-Sadr, Regina Swift, Benjamin Eades, Susanna Kim, Shahrooz Eshaghian, James R Berenson
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients. Targeted oncology (2023)
Scott Jew, Marissa-Skye Goldwater, Sean Bujarski, Bernard Regidor, Marsiye Emamy-Sadr, Regina Swift, Benjamin Eades, Jonathan Said, James R Berenson
The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic. American journal of clinical pathology (2023)
Bernard Sean Regidor, Scott Jew, Marissa-Skye Goldwater, Bethany Marie Beatty, Sean Bujarski, Adam ElSayed, Ryan Danis, Susanna Kim, Regina Swift, Gary Schwartz, James R Berenson
Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression-A single center retrospective study. European journal of haematology (2023)
Sean Bujarski, Christine Sutanto, Tanya M Spektor, Jennifer To, Regina A Swift, Tracy Green, Benjamin R Eades, Marsiye Emamy-Sadr, Eric Souther, James R Berenson
Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. Hematological oncology 40 (2) (2022)
James R Berenson, Daisy Martinez, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Regina Swift, Benjamin M Eades, Sean Bujarski, Bernard Regidor, Clara Kim, Susanna Kim, Robert Vescio
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma. British journal of haematology (2022)
Ning Xu, Erin Yu, Nicole Ng, Mingjie Li, Sean Bujarski, Ava Hekmati, Isabella Nassir, Tara Hekmati, Janna Yu, David Daniely, Cathy S Wang, Clara Kim, Haiming Chen, James R Berenson
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma. Hematological oncology (2022)
James R Berenson, Clara Kim, Sean Bujarski, Jennifer To, Tanya M Spektor, Daisy Martinez, Carley Turner, Matthew Ghermezi, Benjamin M Eades, Regina A Swift, Gary Schwartz, Shahrooz Eshaghian, Robert A Moss, Stephen Lim, Robert Vescio
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Hematological oncology (2022)
Bernard Sean Regidor, Dilawer Siddiqi, Bethany Marie Beatty, Marissa-Skye Goldwater, Scott Jew, Sean Bujarski, Regina Swift, Susanna Kim, James R Berenson
Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody. European journal of haematology (2022)
Samuel David Stampfer, Marissa-Skye Goldwater, Scott Jew, Sean Bujarski, Bernard Regidor, David Daniely, Haiming Chen, Ning Xu, Mingjie Li, Tracy Green, Eddie Fung, Elias Aquino, Regina Swift, Shahrooz Eshaghian, Kurt Preugschat, Aaron J Feinstein, Tanya M Spektor, James R Berenson
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia 35 (12) (2021)
Kyle A Udd, Sean Bujarski, Eric Wirtschafter, Tanya M Spektor, Matthew Ghermezi, Laura Z Rassenti, Michael E David, Jason D Nosrati, Ashkon A Rahbari, James Wang, Suzie Vardanyan, Nika M Harutyunyan, Julia Linesch, Mingjie Li, Eric Sanchez, Haiming Chen, Thomas J Kipps, James R Berenson
Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. Targeted oncology 14 (5) (2020)
Scott Jew, Sean Bujarski, Camilia Soof, Haiming Chen, Tahmineh Safaie, Mingjie Li, Eric Sanchez, Cathy Wang, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, Eric Souther, Tanya M Spektor, James R Berenson
Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients. British journal of haematology 192 (6) (2020)
Scott Jew, Tiffany Chang, Sean Bujarski, Camilia Soof, Haiming Chen, Tahmineh Safaie, Mingjie Li, Eric Sanchez, Cathy Wang, Tanya M Spektor, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, Eric Souther, James R Berenson
Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment. British journal of haematology 192 (2) (2020)
Haiming Chen, Mingjie Li, Nicole Ng, Erin Yu, Sean Bujarski, Zhengyi Yin, Mingxiang Wen, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S Wang, Ning Xu, Tanya M Spektor, James R Berenson
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. British journal of haematology 192 (3) (2020)
Haiming Chen, Mingjie Li, Eric Sanchez, Camilia M Soof, Sean Bujarski, Nicole Ng, Jasmin Cao, Tara Hekmati, Brian Zahab, Jason D Nosrati, Mingxiang Wen, Cathy S Wang, George Tang, Ning Xu, Tanya M Spektor, James R Berenson
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression. British journal of haematology 188 (2) (2019)
Zachary Gross, Ashkon Rahbari, Eric Wirtschafter, Tanya M Spektor, Kyle A Udd, Sean Bujarski, Michael Ghermezi, Jason D Nosrati, Aleksandra Vidisheva, Benjamin Eades, Gary Cecchi, Tina Maluso, Regina Swift, James R Berenson
Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study. European journal of haematology 100 (6) (2018)
James R Berenson, Robert Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre, Roger Lyons, Wael Harb, Hesham Mohamed, Ali Nourbakhsh, Robert Rifkin
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. American journal of hematology 92 (5) (2017)
Alexa Cohen, Tanya M Spektor, Laura Stampleman, Alberto Bessudo, Peter J Rosen, Leonard M Klein, Thomas Woliver, Marshall Flam, Shahrooz Eshaghian, Youram Nassir, Tina Maluso, Regina A Swift, Robert Vescio, James R Berenson
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma. British journal of haematology 180 (1) (2017)

James R Berenson.css-eqlu8i{font-size:small;padding-left:4px;} (James Berenson)

Publication Activity (10 Years)

Top Topics

Top Venues

James R Berenson (James Berenson)